Background and objective FRED (Flow Re-direction Endoluminal Device, Microvention/Terumo) is a second-generation dual layer flow diverting stent for the treatment of intracranial aneurysm. We aimed to review the experience in a regional hospital in Hong Kong under a new antiplatelet alone protocol.

Methods We retrospectively reviewed all patients with intracranial aneurysms treated with FRED under a new antiplatelet alone protocol in Prince of Wales Hospital in Hong Kong.

Results Twenty patients with fusiform or saccular aneurysms were included. Four patients had previous coil embolization for ruptured aneurysm with radiological recurrence and two patients had previous Neuroform stent-assisted embolization. Two patients were treated during the acute phase of subarachnoid hemorrhage. All patients were able to have FRED deployed for aneurysm treatment. At 12 months, 77% of aneurysms had complete occlusion and 8% of aneurysm had near complete occlusion. Both of the 2 aneurysms covered with overlapping FRED achieved complete occlusion at 12 months. There were no procedure or post-operative stroke or hemorrhage up to last follow up.

Conclusions FRED treatment was safe and feasible. The complete occlusion or near complete occlusion were achieved in 85% of aneurysms at 12 months after FRED treatment for intracranial aneurysm. FRED treatment was safe and feasible in all patients in our study.

Disclosures G. Wong: 2; C; Covidien/Medtronic. 3; C; Microvention/Terumo.